Abstract

Objective
Objective. To evaluate the immediate efficacy and safety profile of percutaneous coronary intervention (PCI) across different clinical presentations of acute coronary syndrome (ACS).
Materials and Methods
We conducted a prospective single-center study of 68 consecutive patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI). Inclusion criteria comprised age 40–85 years and a confirmed diagnosis of either ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), or unstable angina. The primary outcomes were procedural success, defined as successful stent deployment with <30% residual stenosis and Thrombolysis in Myocardial Infarction (TIMI) flow grade 3. Secondary endpoints included key time metrics (e.g., door-to-balloon time), periprocedural complications, and in hospital clinical outcomes. Continuous data are presented as mean ± standard deviation or median (interquartile range), as appropriate. Categorical variables are expressed as numbers (percentages). Intergroup comparisons were performed using Student’s *t*-test or the Mann–Whitney U test for continuous data, and Fisher’s exact test for categorical variables. A two-sided p-value <0.05 was considered statistically significant.
Results
Procedural success was achieved in 96.9% of STEMI patients and 97.2% of NSTEMI patients. The median door-to-balloon time was significantly shorter in the STEMI group compared to the NSTEMI group (68.4 ± 12.1 minutes vs. 102.5 ± 45.8 minutes, respectively; p<0.001). Multivessel coronary artery disease was more prevalent in the NSTEMI cohort (66.7% vs. 43.7%). The overall in-hospital incidence of major adverse cardiovascular events (MACE) was 7.4%, with an all-cause mortality rate of 2.9%. A significant improvement in left ventricular systolic function was observed, evidenced by an increase in the mean left ventricular ejection fraction from 48.8 ± 7.8% at admission to 55.2 ± 3.3% at discharge (p<0.01).
Conclusion
In this study, percutaneous coronary intervention was associated with high procedural efficacy and a favorable safety profile in patients presenting with different types of ACS. The intervention facilitated a significant improvement in myocardial function during the index hospitalization.

Keywords

acute coronary syndrome (ACS) electrocardiography (ECG) echocardiography (EchoCG) percutaneous coronary intervention (PCI) angioplasty immediate outcomes.

Full Text

Download article (PDF)

Full version of the article in PDF format

References

  1. 1. Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. *J Am Coll Cardiol*. 2022;80(25):2361–2371. doi:10.1016/j.jacc.2022.11.005.
  2. 2. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J Acute Cardiovasc Care*. 2024;13(1):55–161. doi:10.1093/ehjacc/zuad107.
  3. 3. Rao SV, O'Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. *J Am Coll Cardiol*. 2025;85(22):2135–2237. doi:10.1016/j.jacc.2024.11.009.
  4. 4. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2018;39(2):119–177. doi:10.1093/eurheartj/ehx393.
  5. 5. Бойцов СА, Алекян БГ, Шахнович РМ, Ганюков ВИ. Что меняется в лечении острого коронарного синдрома в Российской Федерации? *Рациональная фармакотерапия в кардиологии*. 2022;18(6):703–709. doi:10.20996/1819-6446-2022-12-14.
  6. 6. Karkabi B, Meir G, Zafrir B, Jaffe R, Adawi S, Lavi I, et al. Door-to-balloon time and mortality in patients with ST-elevation myocardial infarction undergoing primary angioplasty. *Eur Heart J Qual Care Clin Outcomes*. 2021;7(4):422–426. doi:10.1093/ehjqcco/qcaa037.
  7. 7. Kofoed KF, Kelbæk H, Hansen PR, Torp-Pedersen C, Høfsten D, Kløvgaard L, et al. Early versus standard care invasive examination and treatment of patients with non-ST-segment elevation acute coronary syndrome. *Circulation*. 2018;138(24):2741–2750. doi:10.1161/CIRCULATIONAHA.118.037152.
  8. 8. Zwart B, Ten Berg JM, van 't Hof AW, Tonino PAL, Appelman Y, Liem AH, et al. Indications for an early invasive strategy in NSTE-ACS patients. *Neth Heart J*. 2020;28(3):131–135. doi:10.1007/s12471-019-01337-5.
  9. 9. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. *Circulation*. 2021;144(22):e368–e454. doi:10.1161/CIR.0000000000001029.
  10. 10. Попова ЮВ, Киселев АР, Сагайдак ОВ, Посненкова ОМ, Гриднев ВИ, Ощепкова ЕВ. Применение критериев целесообразности коронарной реваскуляризации у больных острым коронарным синдромом в Российской Федерации (данные федерального регистра). *Кардиологический вестник*. 2018;13(4):17–22. doi:10.17116/Cardiobulletin20181304117.
  11. 11. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary. *Circulation*. 2022;145(3):e4–e17. doi:10.1161/CIR.0000000000001039.
  12. 12. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2021;42(14):1289–1367. doi:10.1093/eurheartj/ehaa575.
  13. 13. Khandy AH, Shiekh R, Nabi T, Sheikh MT, Sheikh RY. Incidence, determinants, and outcome of contrast-induced acute kidney injury following percutaneous coronary intervention at a tertiary care hospital. *Saudi J Kidney Dis Transpl*. 2023;34(3):214–223. doi:10.4103/1319-2442.393994.
  14. 14. Stone GW, Ellis SG, Gori T, Metzger DC, Stein B, Erickson M, et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. *Lancet*. 2018;392(10157):1530–1540. doi:10.1016/S0140-6736(18)32283-9.
  15. 15. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. *Eur J Cardiothorac Surg*. 2018;53(1):34–78. doi:10.1093/ejcts/ezx334.